The documents contained in (or directly accessible from) this Website include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements containing the words "believes", "expects", "anticipates", "plans", "estimates" and similar expressions. For this purpose, any statements that are not statements of historical fact may be deemed to be forward-looking statements. Important factors that may cause actual results to differ from the performance suggested by such forward-looking statements include: the risk that the NDA for oxymorphone ER will not be approved by the FDA; the risk that even if approved, oxymorphone ER will not be commercially successful; dependence on collaborators to, among other things, sell products for which the company receives royalties, file for regulatory approvals, and advance clinical development and commercialization of products; the ability to enter into additional collaborations; uncertainty of success of collaborations; the company’s continued losses and need for funding; the risk of patent litigation; regulatory risks relating to drugs in development; the timing of clinical trials; the timing and outcome of regulatory approval of products and other risks and factors identified in the Company's most recent Annual Report on Form 10 K and subsequent reports filed with the SEC. The company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date such statement was made.